Searching in Pharma & Drug Safety · Search everything
2,369 changes Pharma & Drug Safety
USPTO Patent Application: Neuron Generation from Pluripotent Stem Cells
The USPTO has published a patent application (US20260079153A1) detailing methods for generating mature neurons from pluripotent stem cells. The disclosed methods involve overexpressing specific splicing factors to facilitate the study of neurodegenerative diseases and the accelerated derivation of mature neurons.
USPTO Patent Application for Magnetic Separation of Biological Populations
The USPTO has published a new patent application (US20260079086A1) detailing an apparatus, system, and method for high-yield magnetic separation of biological populations. The application describes a system involving a cell engineering cassette, a fluidic pathway with entrapment features, and a translatable magnet array for separating subpopulations.
USPTO Patent Application: Pathogen Surrogates for Fresh Produce Sanitation
The USPTO has published a patent application (US20260079142A1) detailing pathogen surrogates with DNA tags for verifying sanitation systems in fresh produce processing. The application describes a method using these surrogates to mimic pathogen behavior during sanitation and subsequent DNA detection.
USPTO Patent Application for Tau Phospho Binding Antibodies
The USPTO has published a patent application (US20260079168A1) for Tau phospho binding antibodies and antigen binding fragments thereof. The application, filed on September 15, 2025, relates to methods for detecting Tau phospho (Thr217) and potential diagnostic or therapeutic uses for diseases associated with it.
USPTO Patent Application for Multivalent CLTX-CAR γδ T-cells
The USPTO has published a patent application (US20260078529A1) for multivalent CLTX-CAR γδ T-cells, which are designed for treating cancer or tumors. The application details specific T-cell compositions, pharmaceutical formulations, and methods of co-administering these cells with chemotherapeutic agents.
USPTO Patent Application: Orthogonal Mutations for Heterodimerization
The USPTO has published a patent application (US20260078202A1) detailing orthogonal mutations for heterodimerizing domains, particularly in antibody CH3 domains. This application, filed on April 25, 2025, by Jonathan Harry Davis and Nicholas M. Marshall, describes heterodimeric polypeptides and antibody constructs.
USPTO Patent Application: Ultrasensitive Immunoassay Method and Reagents
The USPTO has published a patent application detailing a new method and reagents for ultrasensitive detection of target molecules using reconstituted functional proteins. The invention aims to improve specificity and signal-to-noise ratios in various assay formats, including those for detecting viruses, bacteria, and proteins.
USPTO Patent Application: Organic Electroluminescent Materials and Devices
The USPTO has published a patent application by Universal Display Corporation for organic electroluminescent materials and devices. The application details organometallic compounds, formulations, and organic light emitting devices (OLEDs) utilizing these compounds.
USPTO Patent Application for Organic Light-Emitting Device Compound
The USPTO has published a patent application (US20260082806A1) for a new compound and an organic light-emitting device incorporating it. The application details a compound of Chemical Formula 1, which may offer low driving voltage, high light emitting efficiency, or a long service life.
USPTO Patent Application for Organic Optoelectronic Device Compound
The USPTO has published a patent application (US20260082808A1) detailing a new compound and composition for organic optoelectronic devices and display devices. The application was filed on September 8, 2025, and published on March 19, 2026.
USPTO Patent Application: Heterocyclic Compound for Organic Light Emitting Devices
The USPTO has published a patent application detailing a novel heterocyclic compound for use in organic light-emitting devices (OLEDs). The application, filed by inventors from South Korea, claims improvements in driving voltage, light emission efficiency, and device lifetime.
USPTO Patent Application: Light Emitting Element and Polycyclic Compound
The USPTO has published a patent application for a novel polycyclic compound and a light emitting element that includes it. The application, filed on November 19, 2025, aims to improve luminous efficiency in light emitting devices.
USPTO Patent Application: Systems for Targeting Cancer Cells
The USPTO has published a new patent application, US20260078200A1, detailing systems and methods for targeting cancer cells using genetically modified immune cells. The application describes novel polypeptides and their use in killing target cancer cells.
USPTO Patent Application for Anti-CD38 Antibodies
The USPTO has published a patent application (US20260078199A1) for anti-CD38 antibodies, therapeutics, and diagnostics. The application, filed on July 14, 2025, details methods for treating autoimmune diseases and diagnostic assays.
Carboxyalkyl Chitosan Patent Application
The USPTO has published a patent application (US20260078203A1) for a carboxyalkyl chitosan. The application details compositions, manufacturing processes, and therapeutic applications in areas such as rheumatology, ophthalmology, and dermatology. The filing date was November 26, 2025.
Anti-PTK7 Antibody Patent Application
The USPTO has published a patent application (US20260078201A1) for an anti-PTK7 antibody. The antibody is described as inhibiting angiogenesis, tumor growth, and cancer, with potential therapeutic applications for angiogenesis-related diseases and PTK7-positive cancers.
USPTO Patent Application: Sjögren's Syndrome Detection and Treatment
The USPTO has published a patent application detailing methods for detecting and treating Sjögren's syndrome using salivary exosomes. The application, filed by inventors from various institutions, outlines novel diagnostic and therapeutic approaches for the autoimmune disease.
USPTO Patent Application: Predicting Disease State by Analyzing cfDNA Fragments
The USPTO has published a patent application (US20260080975A1) filed by Foundation Medicine, Inc. The application describes methods for predicting disease states by analyzing cell-free DNA (cfDNA) fragments. This is a routine publication of a patent application.
USPTO Patent Application: HRD Cancer Classification and Treatment
The USPTO has published a patent application from Foundation Medicine, Inc. detailing systems and methods for classifying and treating homologous repair deficiency (HRD) cancers. The application describes models for identifying HRD-positive tumors and suggests combination therapies, such as FOLFIRINOX, for treatment.
USPTO Patent Application: T cell isolation methods
The USPTO has published patent application US20260079159A1 detailing methods for isolating and expanding specific types of T cells (CD127lo/− regulatory T cells) for potential use in treating immune system disorders. The application was filed on September 12, 2025.
USPTO Patent Application: Pyramidal Meditation Structure Device
The USPTO has published a patent application for a pyramidal meditation structure device. The application, filed by Rein Daloul, describes a structure with vertical beams, walls, an entrance, and integrated pipes with crystals intended to impart healing energy during meditation.
Meningitis Patient Factsheet and Vaccination Advice
The MHRA has published a patient factsheet on meningitis, providing information on the condition, its causes, symptoms, and the role of vaccination. The guidance also advises on reporting vaccine side effects through the Yellow Card scheme.
Microsoft Technology Licensing, LLC Awarded Patent for Anti-lock Hinged Device
The USPTO has granted Microsoft Technology Licensing, LLC a patent for an anti-lock hinged device. The patent, US12577979B2, describes a mechanism designed to prevent over-extension in hinged devices. The filing date for this patent application was October 23, 2023.
USPTO Grants Patent for Single Molecule Peptide Sequencing
The USPTO has granted a patent (US12578345B2) to The University of Texas System for methods of single molecule peptide sequencing. The patent covers techniques for identifying polypeptide sequences within a mixture by immobilizing, labeling, and analyzing the polypeptide.
USPTO Patent for Alzheimer's Detection Kits
The USPTO has granted a patent (US12578344B2) to NEUROQUEST LTD. for compositions, kits, and methods for detecting preclinical Alzheimer's Disease. The patent covers binding agents for biomarkers such as CD163 and scavenger receptors, and methods for diagnosing AD and assessing therapeutic efficacy.
USPTO Patent Grant: Canine TK1 Protein Determination Kit
The USPTO has granted patent US12578340B2 to ALERTIX VETERINARY DIAGNOSTICS AB for a kit to determine canine TK1 protein levels. The kit utilizes specific monoclonal antibodies to detect peptides from canine TK1.
USPTO Patent Grant for Polypeptide Reagent Kit
The USPTO has granted a patent (US12578329B2) to Shimadzu Corporation for a reagent kit containing polypeptides designed for detecting intermolecular interactions. The patent details specific amino acid sequences and their modifications for use in this kit.
USPTO Patent Grant: Bioprobes for Amine Oxidase Enzymes
The USPTO has granted a patent (US12578335B2) to Syntara Limited for novel bioprobes designed to detect and quantify amine oxidase enzymes. These bioprobes are intended for use in assessing enzyme concentrations and inhibition levels in various samples.
USPTO Patent Grant US12581852B2 for Luminescent Material
The United States Patent and Trademark Office (USPTO) has granted patent US12581852B2 to KYULUX, INC. for a compound useful as a light-emitting material. The patent covers specific chemical formulas and their application in organic optical devices.
Samsung Display Patent for Organic Compound Sensor Display
The USPTO has granted Samsung Display Co., Ltd. a patent for an organic compound sensor display. The patent, US12581853B2, covers an organic compound represented by Chemical Formula 1 and its application in sensor-embedded display panels and electronic devices. The filing date was September 28, 2022.
USPTO Patent Grant for Light-Emitting Element
The USPTO has granted patent US12581794B2 for a light-emitting element developed by Semiconductor Energy Laboratory Co., Ltd. The patent covers a specific design for a light-emitting element utilizing a phosphorescent compound and an exciplex formed by organic compounds.
Anti-CSF1R Antibodies and Pharmaceutical Compositions Patent
The USPTO has granted patent US12577309B2 for anti-CSF1R antibodies, pharmaceutical compositions, and their uses. The patent was assigned to DRAGONBOAT BIOPHARMACEUTICAL (SHANGHAI) CO., LTD. and lists six inventors. The patent's abstract describes antibodies against human CSF-1R.
USPTO Patent Grant: Diagnostic Antibodies Against MUC17
The USPTO has granted patent US12577322B2 to Amgen Inc. for diagnostic antibodies against mucin 17 (MUC17). These antibodies and associated detection systems are intended for detecting, quantifying, and monitoring MUC17 related to disease diagnosis, progression, and therapeutic response.
USPTO Patent Grant for Bispecific Antibodies
The USPTO has granted a patent (US12577314B2) to ABL BIO INC. for bispecific antibodies designed to treat diseases related to BCMA and/or 4-1BB proteins. The patent covers the antibody's structure and its therapeutic applications.
US Patent 12577313B2 for Bispecific Antibodies
The USPTO has granted US Patent 12577313B2 for bispecific antibodies targeting claudin 18.2 and 4-1BB, assigned to I-Mab Biopharma US Limited. The patent covers novel antibody designs that can trigger tumor-specific immune responses.
DEA Phoenix Operation Mechanic Results Highlighted
The DEA Phoenix Field Division, in partnership with law enforcement agencies, announced the results of Operation Mechanic. This operation focused on combating fentanyl trafficking and related criminal activities, contributing to a broader national effort to reduce drug-related harm.
DEA Seizes 30,000 Fentanyl Pills and 15 Kgs Powder
The DEA announced the seizure of 30,000 fentanyl pills and 15 kilograms of fentanyl powder as part of Operation FentanylFreeAmerica Phase 2. A trafficker linked to the Sinaloa cartel was arrested during the operation, which involved collaboration with local law enforcement agencies.
FDA Requires Warning on Carbidopa/Levodopa for Vitamin B6 Deficiency Seizures
The FDA is requiring drug manufacturers to add a warning to carbidopa/levodopa products regarding the risk of vitamin B6 deficiency and associated seizures. Healthcare professionals are directed to monitor vitamin B6 levels and supplement as needed.
Cardinal Health Recalls Webcol Alcohol Prep Pads Due to Microbial Contamination
Cardinal Health is voluntarily recalling select lots of Webcolâ„¢ Large Alcohol Prep Pads due to microbial contamination with Paenibacillus phoenicis. The recall is being conducted to the consumer level due to the risk of serious infections. The product was distributed nationwide and internationally.
Swissmedic: Lisdexamfetamine Contraindication for Pheochromocytoma Patients
Swissmedic is updating the contraindications for lisdexamfetamine dimesylate to include patients with pheochromocytoma. This change aims to prevent potentially life-threatening increases in catecholamine levels. The product information for both healthcare professionals and patients will be amended to reflect this new contraindication.
WHO Guidance on Responsible AI in Mental Health
The WHO has released guidance based on expert recommendations for the responsible use of AI in mental health. The guidance emphasizes recognizing generative AI use as a public mental health concern, integrating mental health into AI impact assessments, and co-designing AI tools with experts and individuals with lived experience.
ANSM Safety Alert: Eonis SCID-SMA Kit for Genetic Testing
The French ANSM has issued a safety alert regarding the Eonis SCID-SMA kit for genetic testing, manufactured by Wallac/Revvity. Affected users have been notified directly by the company, and the alert is registered under ANSM reference R2607970.
Philips Radiology Device Safety Alert
The French ANSM has been informed of a safety action initiated by Philips Medical Systems Nederland BV concerning radiology devices. Affected users have received a direct communication from the company regarding this action, registered under ANSM reference R2606927.
FDA Seeks Comment on Priority Voucher Pilot Program
The FDA has published a Federal Register Notice seeking public comment on its Commissioner's National Priority Voucher pilot program. The agency also announced a public hearing on June 12, 2026, to gather stakeholder feedback on various aspects of the program's implementation and effectiveness.
Wisconsin Pharmacy Board Rule Changes
The Wisconsin Pharmacy Examining Board has updated Chapter Phar 7, concerning the Practice of Pharmacy, with changes effective January 1, 2021. These updates were adopted on June 4, 2020, and provide important information for licensees regarding pharmacy practice regulations.
Wisconsin Pharmacy Board Updates and Rule Changes
The Wisconsin Pharmacy Examining Board issued a newsletter on September 17, 2020, providing updates on rule changes, COVID-19 variances, and enforcement actions. A key update concerns changes to administrative rules in Chapter Phar 7, effective January 1, 2021.
Wisconsin Pharmacy Board Rule Updates and Enforcement Actions
The Wisconsin Pharmacy Examining Board has updated administrative rules effective August 1, 2020, affecting rule chapters Phar 6 (Storage) and Phar 17 (Internships). These updates include adoption orders outlining specific changes to storage requirements and internship regulations for licensed pharmacists and interns in Wisconsin.
Wisconsin Pharmacy Board Activities: PDMP, HOPE, Opioid Treatment
The Wisconsin Pharmacy Board is providing an update on its activities, including the implementation of the Prescription Drug Monitoring Program (PDMP), participation in the Heroin, Opiate Prevention and Education (HOPE) legislation, and significant rewrites of Chapters 7 (Pharmacy Practice) and 15 (Sterile Pharmaceuticals) of its rules. The PDMP has seen substantial provider registration and inquiry volume, aiming to curb controlled substance abuse.
DEA Virtual Assembly on Fentanyl Risks
The DEA Omaha Division is promoting a free virtual assembly on fentanyl and fake pill risks for middle and high school educators. The event is scheduled for April 7, 2026, and aims to educate attendees on the dangers associated with these substances.
DEA Miami Combats Illicit Vape and Edible Products
The DEA Miami and Tampa Field Divisions are actively combating illicit vape and edible products containing dangerous controlled substances. This initiative highlights ongoing enforcement efforts to protect community members from these harmful products.